Boorjian anticipates research with nadofaragene firadenovec in settings beyond BCG-unresponsive non-muscle invasive bladder cancer.
Stephen A. Boorjian, MD, professor of urology at Mayo Clinic, Rochester, MN, discusses the next steps with the antibody-drug conjugate (ADC) nadofaragene firadenovec in non-muscle invasive bladder cancer (NMIBC).
In a pivotal phase 3 trial of patients with BCG-unresponsive NMIBC, nadofaragene firadenovec achieved a complete response (CR) rate of 53.4% at 3 months in a subgroup of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 disease. The 12-month CR rate was 24.3% and the median duration of CR was 9.69 months in these patients.
Boorjian says that if the ADC receives FDA approval, next steps include combination trials, as well as studying nadofaragene firadenovec in other disease states of NMIBC.